
ELITE PHARMACEUTICALS INC /DE/ Form 8-K
January 27, 2012
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
January 23, 2012
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of Company as specified in its charter)
Delaware 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)
165 Ludlow Avenue, Northvale, New Jersey 07647
(Address of principal executive offices)



(Company's telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events	
On January 23, 2012, the Company received a letter from the US Food and Drug Administration supplement filed by the Company with the agency to change the manufacturing and packaging leydromorphone Hydrochloride Tablets USP, 8 mg ANDA purchased from Mikah Pharma.	
A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is reference herein.	s incorporated by
Item 9.01 Financial Statements and Exhibits	
a) Not applicable.	
b) Not applicable.	
c) Not applicable.	
d) Exhibits	
Exhibit No. Exhibit	
99.1 Press Release dated January 26, 2012	
SIGNATURE	
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly causigned on its behalf by the undersigned hereunto duly authorized.	used this report to be

### ELITE PHARMACEUTICALS, INC.

Dated: January 26, 2012 By: /s/ Chris Dick

Name: Chris Dick

Title: President & Chief Operating Officer